BioSpace News Archive

Company to present corporate update and plans for 2021 Topline TRANQUILITY data expected to be reported by mid-January

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the clinical trial program for NC318, its first-in-class immunomedicine against Siglec15 (S15), a novel immunomodulatory target. “As we continue to review and analyze the available clinical and laboratory data on

OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests A single intratympanic injection of OTO-413 was well-tolerated Otonomy intends to continue clinical development of OTO-413 Management will review results during a conference call today at 8 a.m. ET

Proximie, a global health technology business whose hardware-agnostic, four-camera, remote collaboration platform with augmented reality tools allows the world’s top surgeons to virtually transport themselves into operating rooms anywhere in the world to interact in surgical procedures visually, announces new appointments to its executive team

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and The Commons Project, a non-profit public trust dedicated to building and operating global digital platforms and services for public good, today announced a collaboration that will give individuals more control over how and when they can access their data.

Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases, today announced completing enrollment in its Phase 1 bioimaging study of ifabotuzumab in patients with recurrent glioblastoma multiforme (GBM).

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) is allowing the company’s Investigational New Drug (IND) application to study Annamycin for the treatment of soft tissue sarcoma lung metastases to go into effect

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company delivered an oral and poster presentation today at the RespiDART & Emerging Viruses 2020 meeting.

BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherap

CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (“CRAC”) channels for the treatment of severe acute and chronic inflammatory diseases, today announced that the trial evaluating Auxora™ in patients with severe COVID-19 pneumonia has received a recommendation to continue